Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Atopic Dermatitis
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Ulcerative Colitis
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Amyotrophic Lateral Sclerosis
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Inflammatory Bowel Disease
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Neurodegenerative Diseases
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Glioblastoma Multiforme
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Nonalcoholic Steatohepatitis (NASH)
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Oncology
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Anti-infectives
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Chronic Kidney Disease
AstraZeneca
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
Idiopathic Pulmonary Fibrosis
AstraZeneca
Disease Area
Target ID
Chemistry & Lead Optimisation
Preclinical
Phase 1
Phase 2
20+ Early Discovery Programmes
(multiple indications & targets in therapy areas such as Oncology, Immunology, CNS, GI, Metabolic Disorders and Others)

Case Studies

Dermatology

Atopic Dermatitis

Atopic Dermatitis is the most prevalent type of eczema. The drug we developed to treat the inflammation and itch associated with the disease is currently being tested in human clinical trials.

View Case Study

GASTROENTEROLOGY

Ulcerative Colitis (UC)

UC is a chronic disease with no cure. Our work focuses on discovering safer and more effective small-molecule treatments, and we have identified and validated a novel AI-generated target with no previous link to UC.

View Case Study

ONCOLOGY

Glioblastoma Multiforme (GBM)

GBM is a complex, aggressive and lethal brain tumour. Our work focuses on mechanisms that may contribute to the progression and relapse of the disease, and we advanced one of the most promising candidates through to lead optimisation.

View Case Study

NEURODEGENERATIVE DISORDERS

Amyotrophic Lateral Sclerosis

ALS is a progressive and ultimately fatal neurodegenerative disease. Our two programmes aim to identify targets to treat ALS, and we have progressed two targets to candidate seeking and lead optimization.

View Case Study
Licensing

Drug development licensing partnerships

Our pipeline demonstrates the utility of the Benevolent Platform™, and we are actively exploring strategic licensing partnerships and late-stage development and commercialisation partnerships to deliver our medicines to patients in need.

OUR APPROACH

We innovate at every stage of the drug discovery process

By fusing artificial and human intelligence, we empower scientists to uncover new relationships between diseases and symptoms, drugs and their effects and the subgroups of patients who will respond to treatment.